Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)

Stopped The trial struggled with low activation due to the COVID pandemic. The Steering Committee took the decision to close the accrual in the STEREO trial as of 31 October 2023. It is important to note that no safety concerns have led to this decision.

Conditions

• NSCLC Stage IV
• EGFR Gene Mutation

Interventions

• DRUG: Osimertinib
• RADIATION: Stereotactic Body Radiation Therapy (SBRT)

Sponsor

ETOP IBCSG Partners Foundation

Collaborators

• [object Object]